2012
DOI: 10.1136/bjophthalmol-2011-300686
|View full text |Cite
|
Sign up to set email alerts
|

Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations

Abstract: Cisplatin and MMC inhibit cell growth in conjunctival melanoma cell lines. The potential of ATRA was evident only in combination with MMC or imatinib in CRMM-2 cells. Imatinib and mitomycin increased their efficiency under combination therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 29 publications
0
3
0
1
Order By: Relevance
“…[150] Cisplatin, an organometal and classic alkylating agent used in the treatment of a variety of malignancies, and MMC effectively inhibited growth of the cell lines as single agents. In addition, they reported the combination of imatinib--a selective tyrosine kinase inhibitor most commonly used in treatment of chronic myelogenous leukemia with promising results in malignant melanoma--[47] and MMC had synergistic effects in cell growth inhibition.…”
Section: Treatmentmentioning
confidence: 99%
“…[150] Cisplatin, an organometal and classic alkylating agent used in the treatment of a variety of malignancies, and MMC effectively inhibited growth of the cell lines as single agents. In addition, they reported the combination of imatinib--a selective tyrosine kinase inhibitor most commonly used in treatment of chronic myelogenous leukemia with promising results in malignant melanoma--[47] and MMC had synergistic effects in cell growth inhibition.…”
Section: Treatmentmentioning
confidence: 99%
“…2 Current therapies focus on radical excision of the tumor, and are frequently supplemented with cryotherapy or local therapy. 3,4 The type of additional local treatment is a matter of discussion, although some studies support the use of adjuvant therapy regardless of clinical staging due to the high risk of local recurrence. [5][6][7] However, the rarity of this disease limits the ability to develop randomized clinical trials to determine which adjuvant chemotherapy or new treatment will improve prognosis.…”
mentioning
confidence: 99%
“…期 ATC 患者疗效有限。Ito 等 [9] 在日本进行了一项Ⅱ期临床试验,入组 10 例 ATC 患者,中位无进展存活期 为 2.8 个月,结果显示,索拉非尼可能对 ATC 无效。 研究表明,ATC 异种移植模型中放疗、紫杉醇联合索拉非尼协同作用可降低 ATC 细胞活性,并显著引 起细胞凋亡,降低 ATC 的抗凋亡因子表达,减小肿瘤体积,延长小鼠的存活期 [10] 。Yun 等 [11] 对 HNHA、 索拉非尼联合放疗治疗 ATC 的协同作用进行了研究,结果显示,HNHA 和索拉非尼联合放射治疗可使半胱 氨酸蛋白酶裂解及细胞周期阻滞,从而抑制 ATC 生长。此外,HNHA 联合索拉非尼放射治疗对 ATC 的疗 效优于 HNHA 或索拉非尼放射治疗。因此,HNHA 和索拉非尼联合放射治疗可能成为治疗 ATC 的一种新 方法。 [12] 。Takahashi 等 [13] 进行一项乐伐替尼治疗晚期甲状腺癌患者的有效性及安全性的Ⅱ 期临床试验。研究结果表明,ATC 患者的中位无进展存活期为 7.4 个月,中位总存活期为 10.6 个月,在一 定程度上延长了患者的存活期。Kim 等 [14] [15] 报道了 1 例 74 岁Ⅳ期 ATC 患者,行新辅助治疗后进 行全甲状腺切除术,术后予乐伐替尼 14 mg/d,局部及远处转移病灶部分缓解甚至几乎完全缓解,并且持 续了 14 个月,后因肿瘤进展恶化而死亡。 综上所述,乐伐替尼对 ATC 患者具有一定疗效,有望成为治疗 ATC 的候选药物,但目前病例数仍较 少,须进一步扩大样本量,获得更多临床证据证实其确切疗效。 1.3 安罗替尼 安罗替尼是一种新型多激酶抑制剂,通过抑制 VEGFR、PDGFR、RET、c-Kit 和 FGFR 等激酶来抑制 肿瘤细胞增殖和血管生成。Ruan 等 [16] 研究发现,安罗替尼对 6 种 ATC 及甲状腺乳头状癌细胞均有一定抑 制作用,且动物实验显示安罗替尼可显著抑制小鼠体内移植瘤生长。Gui 等 [17] 报道了一例 67 岁 ATC 患者 术后复发后接受信迪力单抗和安罗替尼联合治疗后肿瘤明显缩小,持续缓解期达 18.3 个月。以上研究表明, 安罗替尼单药或联合治疗可为晚期 ATC 患者提供一种可行的新治疗方式。 1.4 伊马替尼 伊马替尼是一种 BCR-ABL 激酶、c-Kit 受体及 PDGFR 抑制剂,目前主要应用于慢性髓细胞性白血病 及胃肠道间质肿瘤的临床治疗。Ha 等 [18] 进行了一项伊马替尼治疗晚期 ATC 患者的Ⅱ期临床试验,纳入 8 例晚期 ATC 患者,患者部分缓解率为 25%,疾病稳定率为 50%,但完全缓解率为 0%,疗效与细胞毒性化 疗方案相当。因此,单独应用伊马替尼治疗 ATC 的有效性仍需进一步研究。但有研究发现,伊马替尼联合 其他化疗药物可提高肿瘤细胞对抗癌药物的敏感性 [19][20] 。Kim 等 [21]…”
Section: F O R R E V I E W O N L Yunclassified